BARI Investigators Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000 Apr;35(5):1122-9.
Brooks MM, Detre KM The design, patient population and outcomes from the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registries. Semin Interv Cardiol. 1999 Dec;4(4):191-9.
Gurm HS, Whitlow PL, Kip KE; BARI Investigators The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol. 2002 Mar 6;39(5):834-40.
Naydeck BL, Sutton-Tyrrell K, Burek K, Sopko GS Organizational structure and communication strategies of the bypass angioplasty revascularization investigation: a multicenter clinical trial. Control Clin Trials. 1996 Jun;17(3):226-34.
Rautaharju PM, Calhoun HP, Chaitman BR NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol. 1992;24 Suppl:179-87.
Simoons ML Myocardial revascularization--bypass surgery or angioplasty? N Engl J Med. 1996 Jul 25;335(4):275-7.
Srinivas VS, Brooks MM, Detre KM, King SB 3rd, Jacobs AK, Johnston J, Williams DO Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation. 2002 Sep 24;106(13):1627-33.
Yock CA, Boothroyd DB, Owens DK, Winston C, Hlatky MA Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI). Am Heart J. 2000 Oct;140(4):556-64.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.